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ABSTRACT 
 
Different phenotypes of asthma from mild to severe are categorized based on diverse clinical 
features. A guideline for the recognition and treatment of asthma has been provided by Global 
Initiative for Asthma (GINA). To control symptoms and prevent asthma exacerbation in most 
patients combinational therapy with inhaled corticosteroids (ICS) and a long acting B2-adrenreceptor 
agonist (LABA) are recommended. Understanding asthma phenotypes would be helpful to improve 
asthma diagnosis and treatment. The aim of this study was to verify glucocorticoid receptor 
glcococorticoid receptor (GR) nuclear translocation in CD4 T cells treated with fluticasone furoate 
(FF), vilanterol (V) and FF/V combination in severe asthmatic patients compare to patients with 
moderate asthma and healthy controls using Immunocytochemistry (ICC).  
After taking blood and separating PBMCs from each subject, CD4 T cells were isolated from 
PBMCs using CD4+ T cell isolation kit. Isolated CD4 T cells were cultured in presence of FF, V 
and FF/V combination for 1 hour and after cytocentrifugation, cells were incubated with anti GR-
antibody and subsequently stained with FITC bound secondary antibody and GR nuclear 
translocation was observed under microscope.  
The results showed significant increasing in GR nuclear translocation in treated CD4 T cells 
from patients with moderate asthma and controls compare to those severe asthmatic patients, 
along with treating cells with FF/V combination no significant GR nuclear translocation was 
observed compare to that of using mono treatment of cells with FF and V.  
Based on our findings, it can be concluded different mechanisms are responsible for severe 
asthma and moderate asthma. 
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INTRODUCTION 
 
Asthma syndrome comprises distinct variable 
disorders and airway inflammation including wheezing, 
coughing, chest tightness, dyspnea and airway hyper 
responsiveness (AHR).
1
 Different phenotypes of asthma 
from mild to severe are categorized based on diverse 
clinical features. Guideline for the recognition and 
treatment of asthma has been provided by Global 
Initiative for Asthma (GINA).
1
 To control symptoms 
and prevent asthma exacerbation in most patients 
combinational therapy with inhaled corticosteroids 
(ICS) and a long acting β2-adrenreceptor agonist 
(LABA) are indicated.
2
 In 2015, FDA approved inhaled 
fluticasone furoate/vilanterol (FF/V) once daily as a 
treatment strategy for 18 years and older asthmatic 
patients.
1
 Fluticasone furoate is a novel synthetic 
glucocorticoid with high affinity binding to 
glucocorticoid receptors (GR).
3
 Upon binding of the 
ligand, GRs translocate from cytoplasm to the nucleus 
and binds to the glucocorticoid response elements 
(GRE) in the promoter region of steroid sensitive genes. 
This results in switching on β2-adrenergic receptors (2-
ARs) and anti inflammatory genes and suppression of 
cytokines, chemokines, enzymes and receptors which 
are associated with inflammatory responses.
4 β2-
adrenegic receptors are expressed on many cells 
including lymphocytes, mast cells, macrophages, 
epithelial and endothelial cells.
5
Vilanterol is one of the 
potent, selectiveβ2-agonist with a rapid and prolonged 
bronchodilation (over 24 hours) in patients with asthma 
and COPD (5). The benefit of combinational therapy of 
FF/V therapy was assessed in patients with moderate to 
severe asthma.
6-9
 The symptoms of most asthmatic 
patients controlled by ICS and maximum dose of 
ICS/LABA is required to control symptoms of about 
10% of asthmatic patients and there is a small 
proportion of patients who are completely corticosteroid 
resistance and no clinical improvement was defined 
even after high dose of oral corticosteroid.
4
 The airway 
inflammation of these steroid insensitive patients is 
comparable to those with COPD.
4
 This may indicate 
that there are some common mechanisms underlying in 
these diseases.
4
 Understanding asthma phenotypes and 
its diverse clinical features, molecular, cellular, 
morphological and functional characteristics of each 
individual patient would be instructive to improve 
asthma diagnosis and treatment.
10
 Thus, the aim of this 
study was to verify GR translocation in CD4 T cells 
treated with FF, V and in FF/V combination in severe 
asthmatic patients compare to patients with moderate 
asthma and healthy controls using 
Immunocytochemistry (ICC).  
 
MATERIALS AND METHODS 
 
Reagents 
Fluticasone furoate (FF) and vilanterol (V) were 
provided by Glaxo SmithKline (Stevenage, UK). FF 
was dissolved in DMSO at 10 mM concentration and V 
dissolved in PBS at 10 mM concentration, proper 
dilutions were used in the assays ensuring that the 
DMSO concentration was less than 0.5% in the assays.  
 
Subjects 
Five healthy nonsmoking controls, 4 moderate and 
4 severe asthmatic patients (these severe asthmatic 
patients were uncontrolled cases) who defined by 
GINA guidelines (http://www.ginasthma.com) were 
entered the study also the asthma severity of the 
patients were based on ERS/ATS criteria.
10
 After 
taking written informed consent, peripheral blood 
mononuclear cells (PBMCs) of the subjects were 
isolated using ficoll-paque gradients (Ceaderlane, 
Canada). Subsequently, CD4 T cells were separated 
from PBMCs by magnetic cell separation using CD4+ 
T cell isolation kit (Miltenyi Biotec, Germany) 
according to the manufacturer, the purity of the cells 
was confirmed by flowcytometry. 
 
Cell Culture 
CD4+ T cells were cultured in plate-bound Anti-
CD3 antibody (eBioscience, USA). 96 well plates 
containing RPMI-1640 media (Gibco, USA) and 0.1% 
FBS (Gibco, USA) and Anti-CD28 antibody 
(eBioscience, USA) at a density of 200,000 cells/well 
were used. After 18 hours stimulation, cells were 
treated with FF (10
-7  
M), V (10
-7  
M) and FF/V (10
-7 
M/10
-7  
M) for 1 hour and subsequently prepared for 
ICC. The MTT assay was performed before conducting 
the experiment. The used concentration of FF and V 
was based on the previous studies.
11,12
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choosing high concentrations of these drugs was based 
on using high dose treatment of ICS/LABA for severe 
asthmatic patients. 
 
Immuocytochemistry 
Single CD4 T cell suspensions were adhered onto 
microscopic slides using cytocentrifuge to get a 
monolayer cells on the slides. Consequently, cells were 
fixed with formaldehyde solution for 20 minutes at room 
temperature, fixed cells were permeablized with Triton 
X-100 3% and after adding blocking reagent, cells were 
individually incubated with GR (M-20, Santa Cruz 
Biotechnology) at 4˚C over night. Slides were incubated 
with secondary antibody sheep anti-rabbit IgG (H&L) 
FITC conjugated (Agrisera, Sweden) for 40 minutes. 
After washing cells 4, 6-diamidino-2-phenylindole 
dihydrochloride (DAPI), a fluorescent blue nuclear 
indole chromatin stain was used for nuclear staining. 
Subsequently slides were visualized with fluorescent 
microscope. The images were analyzed in the image J 
program. 
 
Statistics Analysis 
The results of the experiments are presented as 
mean±SD. One way ANOVA test was used to compare 
treatment groups. Graph Pad Prism 5 software (Graph 
Pad Prism, San Diego,  CA, USA) was used to analyze 
data, results were considered significant if p Value was 
less than 0.05.  
This study was approved by ethics committee and 
research committee of Immunology, Asthma and Allergy 
Research Institute (IAARI), Tehran University of 
Medical Sciences (Numbers 92-01-40-21242 and 
412/p/277 respectively).  
RESULTS 
 
Subjects 
Four patients with moderate asthma (2 females, 2 
males) and 4 patients with severe asthma (3 females, 1 
male) and five healthy controls (3 females, 2 males) were 
entered the study. The mean age of healthy controls, 
patients with moderate asthma and patients with severe 
asthma were 31.2±3.4, 37.2±14.5 and 47±10.2, 
respectively. All patients were under medication for their 
asthma management (Table 1). Except one patient with 
moderate asthma, all other patients used both ICS/LABA 
for controlling their asthma. 
 
GR Nuclear Translocation in CD4+ T Cells from 
Healthy Controls Compare to the Patients with 
Moderate Asthma (MA) and Severe Asthma (SA) 
CD4 T cells and stimulated CD4 T cells with 
CD3/CD28 antibodies from healthy controls and patients 
with moderate and severe asthma were subjected to ICC 
to evaluate the expression of GR in these cells before 
treatments. All cells in these three groups expressed GR 
diffusely in the cytoplasm around the nuclei membrane 
under microscopy while, GR nuclear expression in CD4 
T cells of control subjects and patients with moderate 
asthma before CD3/CD28 stimulation were 6% and 3%, 
respectively. After stimulating CD4 T cells with 
CD3/CD28 nuclear translocation of GR was increased to 
18% in cells of control patients and 14% in those of MA 
patients. Very rare nuclear translocation was detected in 
the cells of severe asthmatic patients before and after 
stimulation (Figure 1). 
  
 
Table 1. Medications used by asthmatic patient who entered in immunocytochemistry study of CD4 T cells 
Medications MA1 MA2 MA3 MA4 SA1 SA2 SA3 SA4 
inhaled corticosteroid 
(fluticasone/beclomethasone) 
+ + + + + + + + 
ICS/LABA - + + + + + + + 
Inhaled Salbutamol + + + + + + + + 
Leukotriene modifier (Montelukast) - + + - - - - + 
Xanthine (Theophylline, Aminophylline) - - + - + + + - 
ICS: inhaled corticosteroid,  
LABA: long acting B2-adrenreceptor agonist 
MA: moderate asthma, SA: severe asthma 
+: medication was used, -: medication was not used 
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Induction of GR Nclear Translocation in CD4+ T 
Cells Treated with FF, V and FF/V from Healthy 
Controls Compare to the Patients with MA and SA  
Stimulated CD4 T cells from healthy controls and 
patients with MA and SA were treated with FF, V and 
FF/V for 1 hour. The results of ICC showed increased 
translocation of GR in the cells of controls and MA 
patients after treatments while no GR translocation was 
detected in case of severe asthma. More GR 
translocation was observed in cells from patients with 
MA which treated with FF, V and FF/Vcombination 
compare to those of controls (Figure 2). Also, these 
results showed more translocation of GR in treating 
cells with FF and V(the difference is not significant) 
compare to treating them with FF/V combination in 
patients with MA, while no difference of GR nuclear  
 
 
Figure1. I. Immunocytochemistry of glucocorticoid receptor (GR) translocation in CD4 T cells. Nuclear stained CD4 T cells with 
4, 6-diamidino-2-phenylindole dihydrochloride (DAPI) (A), Cells stained with GR-Ab (M-20) and FITC-secondaryAb (B), overlay 
of A and B shows nuclear translocation of GR in CD4 T cells.  
II. GR translocation was increased in CD4 T cells after stimulating with CD3/CD28 antibodies for one hour. In all slides bright 
cells with high density were considered and counted as positive GR translocation and cells with fade color were not taken into the 
account. Left picture is unstimulated CD4 T cells and right picture is stimulated CD4 T cells both from a control subject. 
III. GR translocation was increased in CD4 T cells after stimulating with CD3/CD28 antibodies for one hour. Quantification of 
positive GR nuclear translocation in controls (panel A), patients with moderate asthma (panel B), and patients with severe asthma 
(panel C). The numbers of counted cells are from three independent experiments. 400 cells were counted from four parts of the 
slides, data are presented as mean + SD. (n=3, p*<0.05). 
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Figure 2. I. Glucocorticoid Receptor (GR) translocation was increased in CD4 T cells after treatment with fluticasone furoate 
(FF), vilanterol (V) and Fluticasone furoate /vilanterol (FF/V) for one hour in control subjects (left panel) and patients with 
moderate asthma (right panel). The numbers of counted cells are from three independent experiments. Four hundred cells were 
counted from four parts of the slides, data are presented as mean (n=3, p*<0.05) 
II. GR nuclear translocation was increased in CD4 T cells after treatment with fluticasone furoate (FF), vilanterol (V) and 
fluticasone furoate /vilanterol (FF/V) for one hour in patients with moderate asthma; before treatment (A) after treatment (B). 
The density of GR nuclear translocation was increased remarkably after treatment in control subjects (C), patients with 
moderate asthma (D) but in patients with severe asthma no nuclear GR translocation was visible (E).  
 
 
translocation was detected in the cells from controls 
treated with FF, V and FF/V under microscopy (Figure 
2). It should be noted that after treatment, CD4 T cells 
with positive GR translocation from MA patients were 
Very bright. In all treated groups compare to the 
stimulated cells the density of fluorescent was increased 
remarkably. In all slides bright cells with high density 
were considered and counted as positive GR 
translocation and cells with fade color were not taken 
into the account. 
 
DISCUSSION 
 
This is the first study which was intended to find out 
GR translocation based on ICC in CD4+ T cells from 
healthy controls and patients with MA and SA treated 
with FF, V, and FF/V combination. The results of this 
study showed that the GR nuclear translocation in CD4+ 
T cells from healthy controls and patients with MA at the 
base line was the same without significant difference 
while almost no GR translocation was detected in CD4+ 
A B 
    C                   D                    E 
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T cells of patients with uncontrolled SA. Increasing GR 
translocation was detected in cells of controls and MA 
subjects with FF, V, FF/V treatments, while no 
translocation was observed in cells of patients with SA 
with the different treatments. Previous studies have 
shown significant nuclear translocation of GR in PBMCs 
treated with FF from healthy controls and patients with 
MA.
3
 In asthmatic smooth muscle treated with FF 
different GR translocation was observed in severe 
asthmatic patients compare to patients with moderate 
asthma and healthy controls, although nuclear GR 
baseline levels were similar in these three groups.
12
 In 
human airway epithelial cells high-efficacy of FF as a 
GR agonist was reported in driving GRE-dependent 
transcription.
13
 It is suggested that any GR agonist 
induces transcription in genes dependent manner and FF 
promote most glucocorticoid inducible anti-inflammatory 
genes. Epigenetic and other regulatory elements which 
interferes with 3 D- conformational GR could control 
gene expression in the presence of different 
gluccocorticoids.
13
 Genetic studies have been indicated 
that GR polymorphisms and mutations are not associated 
with GR dysfunction in steroid resistance asthma and 
COPD and in a genome-wide study and some other 
studies in asthmatic patients a functional polymorphism 
was identified in the glucocorticoid induced transcript 1 
(GLCCI1) which is suggested to decline pulmonary 
function of receiving inhaled ICS in asthmatic 
patients.
4,14-16
 Other studies implicated the role of 
proinflammatory cytokines, transcription factors and 
epigenetic factors such as histone acetylation in 
expression and translocation of GR.
4
 
The benefit of combinational therapy of FF/V therapy 
was assessed in patients with moderate to severe asthma 
in several clinical trials.
6,17-20
 Several clinical trials 
suggested that one daily use of FF/V is comparable with 
twice daily use of other ICS/LABAs therapy.
6,20-23
 Based 
on the results of two recent systematic reviews, although 
the combination of FF/V could increase FEV1 versus to 
FF monotherapy and twice daily use of ICS/LABA but, 
no significant clinical difference was observed 
comparing once daily use of FF/V combination to twice 
daily use of ICS/LABA and FF monotherapy.
24,25
 
Molecular studies along with research on the outcomes of 
the combination FF/V therapy would be beneficial for 
controlling asthmatic patients.  
In a study on cells from induced sputum of mild 
asthmatic patients, increase GR translocation and 
expression was observed after combinational therapy.
26
 
The same result was reported in sputum macrophages 
from COPD patients using combination of fluticasone 
propionate and salmeterol.
27
 LABA has been observed to 
increase the effectiveness of ICS in inflammatory 
diseases possibly through up regulation of GRE-
dependent anti inflammatory genes.
4
 The other probable 
mechanism is the improvement of GR translocation to 
the nucleus.
28
 It is suggested that formoterol as a LABA 
could enhance glucocotticoid function by preventing GR 
phophorylation through protein phosphatase 2A.
29
 
Although, according to the ICC results of this study 
combination of FF/V has no significant effect on GR 
translocation in CD4 T cells from controls and MA 
patients compare to singly treatment of FF and V. To 
date there is no reported molecular study to imply the 
effect of vilanterol on asthmatic patients.  
Considering GR transcription level, downstream 
effects of GR transcription and translocation are the 
limitation of our study.  However, these molecular 
studies would be informative regarding different 
responsible mechanisms in MA and SA patients. 
Based on the ICC result of this study, in spite of 
increasing GR translocation in CD4 T cells after 
treatment with FF, V and FF/V, no significant differences 
of GR translocation was observed in combination FF/V 
treatment compare to FF and V treatment in control 
subjects and patients with moderate asthma and almost 
no increasing GR translocation was observed in treated 
cells of uncontrolled severe asthmatic patients. It seems 
the mechanism responsible for uncontrolled asthma is 
different from controlled asthma. Further molecular 
cluster analysis, gene expression and epigenetic studies 
are needed to find the possible effects of these drugs and 
also novel therapeutic strategies should be considered for 
the benefit of uncontrolled SA patients. 
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